FY2025 EPS Estimates for DexCom Decreased by Leerink Partnrs

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for DexCom in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings per share of $2.06 for the year, down from their previous estimate of $2.07. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s Q4 2025 earnings at $0.66 EPS.

DXCM has been the subject of several other research reports. Leerink Partners dropped their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada lowered their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Stifel Nicolaus boosted their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Finally, Sanford C. Bernstein boosted their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Stock Up 0.2 %

Shares of NASDAQ:DXCM opened at $78.10 on Wednesday. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The business has a 50 day simple moving average of $71.24 and a two-hundred day simple moving average of $88.44. The firm has a market capitalization of $30.51 billion, a PE ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Institutional Investors Weigh In On DexCom

Several hedge funds have recently added to or reduced their stakes in the business. Tidal Investments LLC boosted its holdings in DexCom by 68.0% in the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock valued at $2,463,000 after purchasing an additional 14,872 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of DexCom during the 3rd quarter worth about $381,000. World Investment Advisors LLC acquired a new position in shares of DexCom during the 3rd quarter worth about $2,351,000. Sanctuary Advisors LLC raised its position in shares of DexCom by 32.2% during the 3rd quarter. Sanctuary Advisors LLC now owns 14,835 shares of the medical device company’s stock worth $1,080,000 after purchasing an additional 3,615 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its position in shares of DexCom by 59.2% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock worth $381,000 after purchasing an additional 2,111 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,431 shares of company stock valued at $399,319. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.